Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bioavailability of Ubiquinol in Huntington Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by University of Rochester.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Kaneka Corporation
Information provided by:
University of Rochester
ClinicalTrials.gov Identifier:
NCT00980694
First received: September 17, 2009
Last updated: September 18, 2009
Last verified: September 2009

September 17, 2009
September 18, 2009
September 2009
March 2010   (final data collection date for primary outcome measure)
serum coenzyme Q10 levels [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00980694 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Bioavailability of Ubiquinol in Huntington Disease
Bioavailability of Ubiquinol in Huntington Disease

The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals.

Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.

Not Provided
Interventional
Not Provided
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Huntington Disease
Dietary Supplement: ubiquinol
up to 600 mg per day, oral capsules for 8 weeks
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
12
May 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have manifest Huntington disease
  • Be 18 years of age or older
  • Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit
  • Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit

Exclusion Criteria:

  • Have a history of intolerability of sensitivity to CoQ
  • Have an unstable medical or psychiatric illness
  • Be pregnant or breastfeeding; women of childbearing age must use reliable contraception
Both
18 Years and older
No
Contact: Lisa Deuel 585-276-3987 lisa.deuel@ctcc.rochester.edu
Contact: Ryan Evans, MD 585-276-4650 ryan.evans@ctcc.rochester.edu
United States
 
NCT00980694
UQ01
No
Karl Kieburtz, University of Rochester
University of Rochester
Kaneka Corporation
Principal Investigator: Karl Kieburtz, MD University of Rochester
University of Rochester
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP